(NASDAQ: AVTX) Avalo Therapeutics's forecast annual revenue growth rate of 31.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Avalo Therapeutics's revenue in 2025 is $441,000.On average, 1 Wall Street analysts forecast AVTX's revenue for 2029 to be $581,334,135, with the lowest AVTX revenue forecast at $581,334,135, and the highest AVTX revenue forecast at $581,334,135. On average, 2 Wall Street analysts forecast AVTX's revenue for 2030 to be $2,074,126,541, with the lowest AVTX revenue forecast at $94,170,869, and the highest AVTX revenue forecast at $4,054,082,213.
In 2031, AVTX is forecast to generate $4,590,566,815 in revenue, with the lowest revenue forecast at $847,800,868 and the highest revenue forecast at $8,333,332,762.